Keryx Biopharmaceuticals' management team is supported by a multi-disciplinary board of directors. With broad experience in biotechnology, investment management and entrepreneurship, Keryx's board characterizes the Company's mission to develop superior technologies and drugs for the post-genomics era.

Morris Laster, M.D. (Chairman and Chief Executive Officer)
Dr. Laster serves as the Chairman and Chief Executive Officer of Keryx. He was previously employed as Vice President of Medical Venture Capital with Paramount Capital Investments LLC., a New York-based biotechnology venture group. Dr Laster was also a founder of a number of privately held and publicly traded biotechnology companies including Neose Technologies, a publicly traded NASDAQ company. Dr. Laster received his M.D. from Downstate Medical Center, performed post-doctoral training in surgery at Case Western Reserve University Hospital and served as a physician and officer with the paratroopers of the Israel Defense Forces.

Peter Morgan Kash
Mr. Kash has been a Senior Managing Director of Paramount Capital, Inc. and a Director of Paramount Capital Asset Management, Inc. since 1990. From 1989 to 1991, Mr. Kash served as an Associate Professor at the Polytechnic University. In addition, since 1996, he has served as a Lecturer in Entrepreneurship and International Venture Capital at the Wharton School of the University of Pennsylvania and has received an appointment as a visiting professor in entrepreneurship at Nihon University at Tokyo, Japan from 1999 to 2001. He holds a B.S. in Management Science from the State University of New York at Binghamton and an M.B.A. in Finance and Banking from Pace University.

S. Leslie Misrock
Mr. Misrock has been a partner of the law firm of Pennie & Edmonds LLP, a New York-based intellectual property firm, since 1961 and a senior partner since 1970. He is a member of the Visiting Committee of the Department of Biology and Chemistry at MIT, the Association for the Cure of Prostate Cancer (CaP CURE), the Board of Visitors of Fordham Law School, the Health Sciences Board of Columbia University's College of Physicians and Surgeons, and the National Prostate Cancer Coalition. Mr. Misrock is a Director of Cytogen Corporation, a publicly held biopharmaceutical company, as well as a director of several privately held biotechnology and medical informatics companies. Mr Misrock holds an S.B. in Chemistry from the Massachusetts Institute of Technology, an A.M. in Chemistry from Columbia University and an L.L.B. degree from Fordham University.

Mark H. Rachesky, M.D.
Dr. Rachesky is the President of MHR Fund Management LLC, which he founded in 1996. MHR is an investment manager of various private investment funds. Prior to founding MHR, from 1990 to 1996, Dr. Rachesky was employed in various capacities by Carl C. Icahn. He currently also serves as a director of the Samsonite Corporation and Neose Technologies, Inc. Dr. Rachesky received his B.S. from the University of Pennsylvania, and his M.D. and M.B.A. from Stanford University.

Lindsay A. Rosenwald, M.D.
Dr. Rosenwald has served as Chairman of Paramount Capital, Inc., and NASD-member broker-dealer since 1992, Chairman of Paramount Capital Investments LLC, a merchant and investment bank, since 1995, and Chairman of Paramount Capital Asset Management, Inc., which manages the investments of several funds specializing in the technology and biotechnology sectors, since 1994. He is also a director of Neose Technologies, Inc., Interneuron Pharmaceuticals, Inc., and Nephros, Inc. Dr. Rosenwald received his B.S. in Finance from Pennsylvania State University, and his M.D. from Temple University School of Medicine.

Wayne Rothbaum
Mr. Rothbaum is a Managing Director at the Carson Group, a strategic consulting firm providing capital markets intelligence to over 400 publicly traded companies. He has co-managed The Carson Group's life sciences team, which provides services ranging from traditional investor relations to strategic consulting to corporate finance for over 50 life sciences companies, since 1993. In addition, he is a principal at Evolution Capital, an NASD registered broker / dealer, which is a wholly owned subsidiary of The Carson Group. Mr. Rothbaum is also an advisory director to Enzon, Inc. and Maxim Pharmaceuticals, Inc. He received an M.A. from the Elliot School of International Relations at the George Washington University and a B.A. in Cognitive Psychology and Political Science from the State University of New York at Binghamton.